[{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"PAKISTAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Getz Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Mascot Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Inapplicable"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Mascot Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"USV Private Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"USV Private Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"USV Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"||Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Abbott Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remogliflozin Etabonate","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"||Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Teneligliptin Hydrobromide","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Woman's","sponsor":"Our Lady of the Lake Hospital | American Cancer Society | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Oncology","graph2":"Phase IV","graph3":"Woman's","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Woman's \/ Our Lady of the Lake Hospital | American Cancer Society | Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Woman's \/ Our Lady of the Lake Hospital | American Cancer Society | Pfizer Inc"},{"orgOrder":0,"company":"Indiana Hemophilia &Thrombosis Center, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Indiana Hemophilia &Thrombosis Center, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Indiana Hemophilia &Thrombosis Center, Inc. \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Indiana Hemophilia &Thrombosis Center, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centre for Addiction and Mental Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Addiction and Mental Health \/ Inapplicable"},{"orgOrder":0,"company":"Promomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Promomed \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Promomed \/ Inapplicable"},{"orgOrder":0,"company":"Christiana Care Health Services","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Christiana Care Health Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Christiana Care Health Services \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Christiana Care Health Services \/ Inapplicable"},{"orgOrder":0,"company":"Purpose Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Purpose Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Purpose Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Purpose Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Canadian Cancer Society","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Neurology","graph2":"Phase III","graph3":"Canadian Cancer Society","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canadian Cancer Society \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Cancer Society \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"||Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hua Medicine \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Hua Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"||SLC5A2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enavogliflozin","moa":"||SLC5A2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Population Health Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Population Health Partners","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Population Health Partners"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hamilton Health Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Center Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CS02","moa":"||HbA1c","graph1":"Endocrinology","graph2":"Phase II","graph3":"Center Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Center Laboratories \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Center Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Metformin","moa":"||Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ CUREator","highestDevelopmentStatusID":"8","companyTruncated":"George Medicines \/ CUREator"},{"orgOrder":0,"company":"Macleods Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Macleods Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Macleods Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Macleods Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Exemed Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Exemed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Bilayer","sponsorNew":"Exemed Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Exemed Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"National Institute for Health and Care Research","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Galantamine Hydrobromide","moa":"||Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rejuvenate Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rejuvenate Biomed \/ National Institute for Health and Care Research","highestDevelopmentStatusID":"8","companyTruncated":"Rejuvenate Biomed \/ National Institute for Health and Care Research"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"FARMAK, a.s \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FARMAK, a.s \/ Inapplicable"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"FARMAK, a.s \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FARMAK, a.s \/ Inapplicable"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"FARMAK, a.s \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FARMAK, a.s \/ Inapplicable"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet, Prolonged Release","sponsorNew":"FARMAK, a.s \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FARMAK, a.s \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Hydrobromide","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rejuvenate Biomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rejuvenate Biomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rejuvenate Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Sidra Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hamad Medical Corporation \/ Sidra Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Sidra Medicine"},{"orgOrder":0,"company":"Metabolic Research Unit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Metabolic Research Unit","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metabolic Research Unit \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Metabolic Research Unit \/ Inapplicable"},{"orgOrder":0,"company":"Taipei City Hospital","sponsor":"The One Biopharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Taipei City Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Taipei City Hospital \/ The One Biopharmaceutical Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Taipei City Hospital \/ The One Biopharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Kyu Chang Won","sponsor":"Boryung Pharmaceutical Co., Ltd | Dong-A ST Co., Ltd. | HK inno.N | Daewoong Pharmaceutical | Chong Kun Dang Pharm | Celltrion | Kakao Healthcare | HANDOK","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Kyu Chang Won","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyu Chang Won \/ Boryung Pharmaceutical Co., Ltd | Dong-A ST Co., Ltd. | HK inno.N | Daewoong Pharmaceutical | Chong Kun Dang Pharm | Celltrion | Kakao Healthcare | HANDOK","highestDevelopmentStatusID":"1","companyTruncated":"Kyu Chang Won \/ Boryung Pharmaceutical Co., Ltd | Dong-A ST Co., Ltd. | HK inno.N | Daewoong Pharmaceutical | Chong Kun Dang Pharm | Celltrion | Kakao Healthcare | HANDOK"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chiglitazar Sodium","moa":"||PPA receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"||Dipeptidyl peptidase IV","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"United Health Group | Northwestern University | Hennepin County Medical Center, Minneapolis | University of Colorado, Denver | Olive View-UCLA Education & Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ United Health Group | Northwestern University | Hennepin County Medical Center, Minneapolis | University of Colorado, Denver | Olive View-UCLA Education & Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"University of Minnesota \/ United Health Group | Northwestern University | Hennepin County Medical Center, Minneapolis | University of Colorado, Denver | Olive View-UCLA Education & Research Institute"},{"orgOrder":0,"company":"Anji Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anji Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Military Institute of Medicine","sponsor":"ABM Industries","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Military Institute of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Military Institute of Medicine \/ ABM Industries","highestDevelopmentStatusID":"10","companyTruncated":"Military Institute of Medicine \/ ABM Industries"},{"orgOrder":0,"company":"Amsterdam UMC","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Amsterdam UMC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Amsterdam UMC \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Amsterdam UMC \/ ZonMw"},{"orgOrder":0,"company":"University of Hawaii","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Hawaii","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hawaii \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"University of Hawaii \/ Merck & Co"},{"orgOrder":0,"company":"Stanford University","sponsor":"Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Kaiser Permanente | VA Palo Alto Health Care System | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ Inapplicable"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"The Research Council of Norway | Norwegian Diabetes Association | South-Eastern Norway Regional Health Authority | University of Oslo | Akershus University Hospital | Vestre Viken Hospital Trust | University of Glasgow","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ The Research Council of Norway | Norwegian Diabetes Association | South-Eastern Norway Regional Health Authority | University of Oslo | Akershus University Hospital | Vestre Viken Hospital Trust | University of Glasgow","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ The Research Council of Norway | Norwegian Diabetes Association | South-Eastern Norway Regional Health Authority | University of Oslo | Akershus University Hospital | Vestre Viken Hospital Trust | University of Glasgow"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanwu Hospital, Beijing \/ Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Xuanwu Hospital, Beijing \/ Institute of Zoology, Chinese Academy of Sciences | Beijing Institute of Genomics, Chinese Academy of Sciences | Merck Group"},{"orgOrder":0,"company":"Vitality in Aging Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Vitality in Aging Research Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitality in Aging Research Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vitality in Aging Research Group \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Laboratory of Clinical and Experimental Pharmacology","sponsor":"Arab Society of Pharmaceutical Industries | Centre National Chalbi Belkahia de Pharmacovigilance- Tunisia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratory of Clinical and Experimental Pharmacology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratory of Clinical and Experimental Pharmacology \/ Arab Society of Pharmaceutical Industries | Centre National Chalbi Belkahia de Pharmacovigilance- Tunisia","highestDevelopmentStatusID":"6","companyTruncated":"Laboratory of Clinical and Experimental Pharmacology \/ Arab Society of Pharmaceutical Industries | Centre National Chalbi Belkahia de Pharmacovigilance- Tunisia"},{"orgOrder":0,"company":"Laboratory of Clinical and Experimental Pharmacology","sponsor":"Laboratoires SAIPH | Centre National Chalbi Belkahia de Pharmacovigilance- Tunisia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratory of Clinical and Experimental Pharmacology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratory of Clinical and Experimental Pharmacology \/ Laboratoires SAIPH | Centre National Chalbi Belkahia de Pharmacovigilance- Tunisia","highestDevelopmentStatusID":"6","companyTruncated":"Laboratory of Clinical and Experimental Pharmacology \/ Laboratoires SAIPH | Centre National Chalbi Belkahia de Pharmacovigilance- Tunisia"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Alexandria University","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Alexandria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexandria University \/ Eva Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Alexandria University \/ Eva Pharma"},{"orgOrder":0,"company":"Alfred E Tiefenbacher GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Alfred E Tiefenbacher GmbH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfred E Tiefenbacher GmbH \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alfred E Tiefenbacher GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Alfred E Tiefenbacher GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Alfred E Tiefenbacher GmbH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfred E Tiefenbacher GmbH \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alfred E Tiefenbacher GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Elaine Chow","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Elaine Chow","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elaine Chow \/ Merck Group","highestDevelopmentStatusID":"1","companyTruncated":"Elaine Chow \/ Merck Group"},{"orgOrder":0,"company":"PT Pyridam Farma Tbk","sponsor":"Pharma Metric Labs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial glycerol-3-phosphate dehydrogenase","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"PT Pyridam Farma Tbk","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT Pyridam Farma Tbk \/ Pharma Metric Labs","highestDevelopmentStatusID":"1","companyTruncated":"PT Pyridam Farma Tbk \/ Pharma Metric Labs"}]

Find Clinical Drug Pipeline Developments & Deals for Riomet

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Vildagliptin,Metformin

                          Therapeutic Area : Endocrinology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : MefoVil (vildagliptin & metformin hydrochloride) is an antibiotic drug, which is indicated for the treatment of type 2 diabetes mellitus.

                          Product Name : MefoVil

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 17, 2025

                          Lead Product(s) : Vildagliptin,Metformin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Towa Pharmaceutical

                          02

                          Lead Product(s) : Saxagliptin,Metformin

                          Therapeutic Area : Endocrinology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Saxagliptin and Metformin Hydrochloride extended-release tablets is a dipeptidyl peptidase-4 (DPP4) inhibitor and biguanide combination product indicated for adults with type 2 diabetes mellitus.

                          Product Name : Kombiglyze-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 08, 2023

                          Lead Product(s) : Saxagliptin,Metformin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          03

                          Lead Product(s) : Vildagliptin,Metformin

                          Therapeutic Area : Endocrinology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.

                          Product Name : Vildagliptin-Metformin-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 09, 2022

                          Lead Product(s) : Vildagliptin,Metformin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Tiefenbacher Compnay Banner

                          04

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Study Phase : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 20, 2022

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Tiefenbacher Compnay Banner

                          05

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Study Phase : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 15, 2022

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Tiefenbacher Compnay Banner

                          06

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Farmak Company Banner

                          07

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Farmak Company Banner

                          08

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Farmak Company Banner

                          09

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 17, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Farmak Company Banner

                          10

                          Lead Product(s) : Metformin

                          Therapeutic Area : Endocrinology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Granules India has been granted final FDA approval for its Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg, generic equivalent of Glumetza ER Tablets, 500 mg and 1000 mg, of Bausch Hea...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 13, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Granules India